219 related articles for article (PubMed ID: 18365002)
1. Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.
Wee KB; Pramono ZA; Wang JL; MacDorman KF; Lai PS; Yee WC
PLoS One; 2008 Mar; 3(3):e1844. PubMed ID: 18365002
[TBL] [Abstract][Full Text] [Related]
2. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC
Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
[TBL] [Abstract][Full Text] [Related]
3. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites.
Aartsma-Rus A; De Winter CL; Janson AA; Kaman WE; Van Ommen GJ; Den Dunnen JT; Van Deutekom JC
Oligonucleotides; 2005 Dec; 15(4):284-97. PubMed ID: 16396622
[TBL] [Abstract][Full Text] [Related]
5. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
6.
Goossens R; Verwey N; Ariyurek Y; Schnell F; Aartsma-Rus A
RNA Biol; 2023 Jan; 20(1):693-702. PubMed ID: 37667454
[TBL] [Abstract][Full Text] [Related]
7. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
8. Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.
O'Leary DA; Sharif O; Anderson P; Tu B; Welch G; Zhou Y; Caldwell JS; Engels IH; Brinker A
PLoS One; 2009 Dec; 4(12):e8348. PubMed ID: 20020055
[TBL] [Abstract][Full Text] [Related]
9. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
Hiller M; Spitali P; Datson N; Aartsma-Rus A
Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
[TBL] [Abstract][Full Text] [Related]
10. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
11. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
[TBL] [Abstract][Full Text] [Related]
14. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides.
Bremmer-Bout M; Aartsma-Rus A; de Meijer EJ; Kaman WE; Janson AA; Vossen RH; van Ommen GJ; den Dunnen JT; van Deutekom JC
Mol Ther; 2004 Aug; 10(2):232-40. PubMed ID: 15294170
[TBL] [Abstract][Full Text] [Related]
15. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
16. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
Dzierlega K; Yokota T
Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212
[TBL] [Abstract][Full Text] [Related]
17. The Pharmacokinetics of 2'-
Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J
Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628
[TBL] [Abstract][Full Text] [Related]
18. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
Falzarano MS; Passarelli C; Ferlini A
Nucleic Acid Ther; 2014 Feb; 24(1):87-100. PubMed ID: 24506782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
